IN.PACT Admiral Drug-Coated Balloon
Maintain long-term vessel patency with the IN.PACT™ Admiral™ drug-coated balloon (DCB), which provides durable, consistent, and safe outcomes across multiple clinical trials, as well as across complex patient and lesion types. With more than 3,500 patients enrolled in 21 clinical studies and 200,000+ patients treated, the IN.PACT Admiral balloon is the market-leading DCB for treatment of femoropopliteal disease with 75% of patients reintervention-free at 5 years.1 This matters now more than ever.†
Please note the Instructions for Use were updated recently to include enhanced information on paclitaxel safety. Please follow the “indications, safety, and warnings” link at the top of this page for more information.
The IN.PACT Admiral paclitaxel-coated PTA balloon catheter is indicated for percutaneous transluminal angioplasty, after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions with up to 360 mm in superficial femoral or popliteal arteries with reference vessel diameters of 4–7 mm.
The IN.PACT Admiral DCB is a clinically proven, primary endovascular therapy that treats femoropopliteal disease, reduces interventions, and preserves future treatment options.
IN.PACT Admiral DCB, with sustained drug release up to 180 days,2 has the:
Highest patency benefit through 3 years‡3
Lowest CD-TLR rates and lowest mortality through 5 years1,4
Most publications for a DCB§